Islet amyloid polypeptides with improved solubility

US10683333B2 · kind B2 · utility

Assignee

• The Research Foundation for The State University of New York · US

Inventors

• Daniel Raleigh · Stony Brook, US
• Hui Wang · East Setauket, US
• Ping Cao · San Jose, US
• Andisheh Abedini · New York, US

Key dates

• Filing date: Jul 11, 2018
• Grant date: Jun 16, 2020
• Expiry date: Jul 11, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Isolated non-naturally occurring, mutant-human islet amyloid polypeptides (hIAPP) are disclosed. These polypeptides can be formulated or co-formulated at physiological pH, which enable the polypeptides of the instant disclosure to be delivered to a subject having an amyloid-based disease in a single injection with an insulin agent. Methods and compositions for treating amyloid-based disease in a subject in need thereof, by administering an effective amount of an isolated, mutant-hIAPP polypeptide, including formulations or co-formulations thereof are also disclosed.